Compare Southern Copper Corp (SCCO) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southern Copper Corp vs Sanofi SA — how do they compare? Southern Copper Corp trades at $193.73 (market cap $164.21B), while Sanofi SA trades at $43.61 (market cap $104.30B). The key difference: Southern Copper Corp is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| SCCO | SNY | |
|---|---|---|
Market Cap | $164.21B | $104.30B |
Sector | Basic Materials | Health |
52-Week High | $218.85 | $52.34 |
52-Week Low | $93.70 | $41.33 |
Enterprise Value | $165.50B | $124.19B |
Dividend Yield | 2.26% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southern Copper (SCCO) trades at $193.14, down 3.48% on the day, amid a broader copper price pullback. The stock exhibits strong fundamentals with revenue growth from $13.42B in 2025 to a projected $15.8B in 2026 and robust profitability margins, including a net income margin of 35.87%. Recent quarters have consistently beaten EPS estimates, and technical indicators show a bullish trend with key support at $191. However, the stock trades at a premium valuation with a P/E of 29.18, above the analyst consensus price target of $153.64.
The outlook for SCCO is mixed; strong earnings growth and exposure to copper demand from AI and data centers present upside, but high valuation and reliance on volatile metal prices pose risks. Analyst sentiment is cautious with only 10.34% buy ratings, suggesting limited near-term upside from current levels despite solid operational performance.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
